SEC Tracker
Get the app

Pluri PLUR

Pluri FY 2024: revenue $326K, up 14%; diluted EPS −$3.99

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Pluri reported for the year ended Jun 30, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$326K+14% from $287K in FY 202310-K income statement, on EDGAR
  2. Net income−$20.9MAgainst −$28.3M in FY 202310-K income statement, on EDGAR
  3. Diluted EPS−$3.99Against −$0.78 in FY 202310-K income statement, on EDGAR
  4. Cash and cash equivalents$6.8M+27% from $5.4M in FY 202310-K balance sheet, on EDGAR
  5. Cash from operations−$18.0MAgainst −$22.9M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Pluri files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. ProPhase Labs PRPH public float $15M, Jun 30, 2025
  2. Akari Therapeutics AKTX public float $15M, Jun 30, 2025
  3. X4 Pharmaceuticals XFOR public float $15M, Jun 30, 2025
  4. CalciMedica CALC public float $16M, Jun 30, 2025
  5. Lipocine LPCN public float $16M, Jun 30, 2025